(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of 154.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.96%.
Immutep's revenue in 2026 is $6,708,683.On average, 6 Wall Street analysts forecast IMMP's revenue for 2026 to be $34,783,558,897, with the lowest IMMP revenue forecast at $5,724,727,134, and the highest IMMP revenue forecast at $47,180,806,000. On average, 5 Wall Street analysts forecast IMMP's revenue for 2027 to be $6,666,678,410, with the lowest IMMP revenue forecast at $0, and the highest IMMP revenue forecast at $14,657,930,164.
In 2028, IMMP is forecast to generate $193,881,319,977 in revenue, with the lowest revenue forecast at $11,177,821,807 and the highest revenue forecast at $634,831,348,253.